Methods Projects

This study is a replication of the drug utilization study conducted by INESSS using data from Quebec to gather data from 6 additional provinces. The objectives are to identify incident and prevalent cases of major neurocognitive disorder among older adults and describe their characteristics and a set of indicators of the use of potentially inappropriate medications. The results from the Quebec study will be included into the overall findings.

This study will replicate a FDA Sentinel study using the CNODES' adaptation of the Sentinel Common Data Model with Canadian data to determine whether there is an increased risk of intentional self-harm among adult patients with diabetes who are newly treated with GLP-1 receptor agonists compared to those who are newly treated with SGLT-2 inhibitors or DPP-4 inhibitors.

This study will determine the percentage of patients with familial hypercholesterolemia achieving the public drug plans' recommended treatment goals with PCSK9 inhibitors and estimate the incidence of major adverse cardiovascular events among patients with familial hypercholesterolemia who are prescribed PCSK9 inhibitors. This project is a collaboration with ADTEC.

We updated our previous study to describe fluoroquinolone utilization trends from 2008 to 2022 and to assess the impact of the risk minimization measures introduced by Health Canada in 2017. Fluoroquinolone use declined in the outpatient setting over the study period, and findings suggest that the regulatory actions could have affected the prescribing of fluoroquinolones.

This study will describe the utilization of long-acting inhaled therapies for COPD in 6 provinces between 2012 and 2024, describing the characteristics of patients at treatment initiation and how treatment evolves over time.

As part of a collaboration with International Coalition of Medicines Regulatory Authorities (ICMRA), we will replicate a study conducted by DARWIN EU to describe the characteristics of patients prescribed a glucagon-like peptide-1 receptor agonist and patterns of use between 2015 and 2025.